gms | German Medical Science

Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2014)

28.10. - 31.10.2014, Berlin

Sphingolipids in human osteoarthritic synovial fluid

Meeting Abstract

  • presenting/speaker Marta Kosinska - Universität Gießen, Orthopädische Universitätsklinik, Labor für Experimentelle Orthopädie, Gießen, Germany
  • Gerhard Liebisch - Universitätsklinik Regensburg, Institut für Klinische Chemie und Laboratoriumsmedizin, Regensburg, Germany
  • Guenter Lochnit - Universität Gießen, Biochemisches Institut des FB Medizin, Gießen, Germany
  • Jochen Wilhelm - Universität Giessen, Medizinische Klinik II/IV, Gießen, Germany
  • Ulrich Kaesser - Internistisches Praxiszentrum, am Krankenhaus Balserische Stiftung, Gießen, Germany
  • Markus Rickert - Universität Gießen, Orthopädische Universitätsklinik, Labor für Experimentelle Orthopädie, Gießen, Germany
  • Gerd Schmitz - Universitätsklinik Regensburg, Institut für Klinische Chemie und Laboratoriumsmedizin, Regensburg, Germany
  • Juergen Steinmeyer - Universität Gießen, Orthopädische Universitätsklinik, Labor für Experimentelle Orthopädie, Gießen, Germany

Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2014). Berlin, 28.-31.10.2014. Düsseldorf: German Medical Science GMS Publishing House; 2014. DocPO12-1089

doi: 10.3205/14dkou601, urn:nbn:de:0183-14dkou6010

Veröffentlicht: 13. Oktober 2014

© 2014 Kosinska et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: Synovial fluid (SF) of articular joints is involved in nutrition, cell communication, shock absorption, and surface lubrication. Any altered composition might be associated with the pathophysiology of a certain joint disease. We already quantified 130 glycerophospholipid species in human osteoarthritis (OA) and rheumatoid arthritis (RA) SF. This lipidomic investigation now aims to quantify, for the first time, the composition of sphingolipids in the SF of knee joints from unaffected controls and from patients with early (eOA) and late (lOA) stages of OA, and RA.

Method: Lipids were extracted from SF samples free of cells and cellular debris of 9 postmortem donors (control), 17 eOA, 13 lOA, and 18 RA patients. Sphingolipids were quantified using electrospray ionization tandem mass spectrometry directly or coupled with hydrophilic interaction liquid chromatography. The quantitative values of sphingolipids were corrected for possible dilution of SF according to the method described by Kraus et al. (2002). This study was approved by the local ethics committee of our university, and all patients provided written informed consent. The Kruskal-Wallis test adjusted with a false discovery rate (FDR) of 10% and the Wilcoxon rank sum test were used to determine statistically significant differences. P values of less than 0.05 were considered to be statistically significant.

Results and conclusion: We provide a novel, detailed overview of sphingolipids present in human SF. The analytical set-up used in the present study allowed us to quantitate 35 different sphingolipids. Based on the length and saturation of the attached fatty acids, 19 sphingomyelin species, 6 ceramide species, 5 hexosylceramide and 5 dihexosylceramide species were identified in SF. Remarkably, when compared to control SF, all species were found to be elevated in eOA, lOA and RA SF. Moreover, sphingomyelin species rose approximately 2-fold in SF from eOA to lOA and nearly 1.5-fold in SF from eOA to RA. In addition, the levels of ceramide species rose approximately 1.7-fold in SF from eOA to RA, and nearly 1.3-fold in SF from lOA to RA.

Our lipidomic investigation displays for the first time a detailed overview of sphingolipids in human SF. Compared to control SF the concentrations of sphingolipids were found to be elevated in eOA, lOA and RA SF. Sphingolipids can alter synovial inflammation and the repair responses of damaged joints thus, sphingolipids appear to be associated with the pathogenesis of most prevalent joint diseases.